ALKS — Alkermes plc stock price, charts and financials

QT63Alkermes plc

Alkermes plc (NASDAQ: ALKS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
49.67
+0.14+0.28%
OverviewShort InterestFilings
ALKSQT63Alkermes plc·NASDAQ
49.67+0.28%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
APGE+0.06%$134.19KYMR+4.07%$104.39IMVT+2.21%$39.36PRAX+1.49%$310.07PTGX+2.67%$135.81PCVX+2.17%$54.69CRNX+0.12%$83.86SYRE+10.54%$104.94
Snapshot
Index-P/E130.71EPS (ttm)0.38Insider Own1.89%Shs Outstand167.76MPerf Week-1.64%
Market Cap8.33BForward P/E72.92EPS next Y0.68Insider Trans-4.53%Shs Float155.14MPerf Month-9.92%
Enterprise Value9.24BPEG-EPS next Q-0.02Inst Own107.00%Short Float9.68%Perf Quarter45.36%
Income67.00MP/S5.00EPS this Y-225.98%Inst Trans-Short Ratio6.78Perf Half Y42.08%
Sales1.67BP/B4.61EPS next Y242.28%ROA1.51%Short Interest15.02MPerf YTD77.52%
Book/sh10.78P/C12.68EPS next 5Y-ROE3.72%52W High55.67 -10.78%Perf Year87.08%
Cash/sh3.92P/FCF37.08EPS past 3/5Y-ROIC2.12%52W Low25.17 97.34%Perf 3Y72.71%
Dividend Est.-EV/EBITDA42.39Sales past 3/5Y9.90% 7.27%Gross Margin84.56%Volatility4.40% 3.45%Perf 5Y105.76%
Dividend TTM-EV/Sales5.54EPS Y/Y TTM-82.49%Oper. Margin7.03%ATR (14)1.96Perf 10Y-0.90%
Dividend Ex-Date-Quick Ratio1.85Sales Y/Y TTM7.06%Profit Margin3.96%RSI (14)47.08Recom2.55
Dividend Gr. 3/5Y-Current Ratio2.30EPS Q/Q34.62%SMA20-3.83%Beta0.26Target Price55.86
Payout0.00%Debt/Eq0.04Sales Q/Q26.85%SMA502.98%Rel Volume0.59Prev Close49.53
Employees2,050LT Debt/Eq0.03EarningsOct 28SMA20039.23%Avg Volume2.26MPrice49.67
IPO DateJul 16, 1991Option/ShortYes / YesEPS/Sales Surpr.2649.81% 8.45%Net Debt/EBITDA4.87Volume1,342,207Change0.28%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ReiteratedPiper SandlerOverweight$45 → $65
Jul-20-26ReiteratedStifel Nicolaus$36 → $63
Jul-02-26ReiteratedMizuhoOutperform$45 → $65
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
Jun-18-26ReiteratedNeedhamBuy$50 → $54
Jun-09-26ReiteratedRBC CapitalOutperform$47 → $56
May-06-26ReiteratedNeedhamBuy$43 → $50
Feb-26-26ReiteratedH.C. WainwrightNeutral$46 → $43
Feb-23-26InitiatedWolfe ResearchOutperform$45
Oct-28-25ReiteratedJefferiesBuy$50 → $56
Latest News
Aug-03-26
Aug-03-2605:08AM
Alkermes plc $ALKS Shares Sold by Glenmede Trust Co. NAdefenseworld.net
Jul-31-26
Jul-31-2607:27PM
Alkermes plc 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
Jul-28-26
Jul-28-2603:03PM
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcriptseekingalpha.com
12:26PM
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Downzacks.com
10:31AM
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metricszacks.com
10:06AM
Alkermes Q2 Earnings Call Highlightsmarketbeat.com
09:16AM
Alkermes (ALKS) Reports Break-Even Earnings for Q2zacks.com
07:00AM
Alkermes plc Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-21-26
Jul-21-2601:26PM
Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha
11:06AM
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?zacks.com
Jul-20-26
Jul-20-2610:44AM
Stifel Reiterates Buy on Alkermes, Raises Price Target to $63Benzinga
Jul-14-26
Jul-14-2604:00PM
Alkermes to Report Second Quarter Financial Results on July 28, 2026businesswire.com
Jul-13-26
Jul-13-2611:48AM
Needham Maintains Buy on Alkermes, Raises Price Target to $62Benzinga
07:00AM
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysisbusinesswire.com
Jul-08-26
Jul-08-2608:10AM
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without PenaltiesBenzinga
Company

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ownership
Total institutional ownership107.00%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,6681,4761,5581,6631,1121,1741,0391,1711,094
Cost of Goods Sold Incl. D&A258196245253218197178180176
Gross Profit1,4101,2791,3121,410894976860991918
Selling, General and Administrative Excl. Other845715645690591550539599526
Research and Development391324245271273291395513425
Other Operating Expense58-142353638395466
Operating Income117254421414-698-112-175-99
Interest Expense59122323131191415
Unusual Expense
—————————
Non-Operating Income (Expense)40504630-12125-8-12
Net Income Before Taxes97291444422-3188-97-197-127
Income Taxes325072-9821114012
Consolidated Net Income67242367356-158-48-111-197-139
Net Income From Continuing Operations67242372519-3376-111-197-139
Net Income67242367356-158-48-111-197-139
EPS (Recurring)0.401.472.222.14-0.97-0.30-0.70-1.25-0.90
EPS (Basic, Before Extraordinaries)0.401.472.222.14-0.97-0.30-0.70-1.25-0.90
EPS (Diluted)0.381.432.172.10-0.97-0.30-0.70-1.25-0.90
EBITDA21833149551960178-6-103-8
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio130.7119.5713.2513.21—————
Price To Sales Ratio4.973.133.052.773.853.193.052.744.18
Gross Margin84.5386.6584.2184.7980.4083.1382.7784.6383.91
Operating Margin7.0117.2127.0224.89-0.548.35-10.78-14.94-9.05
Net Margin4.0216.4023.5621.41-14.21-4.09-10.68-16.82-12.71
Shares Outstanding167165165166164161159157155
Market Capitalization8,2954,6174,7454,6054,2853,7453,1723,2034,574
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$59.58$50.13$40.67$31.22$21.77● Close Price0.00M0.69M1.39M2.08M2.78MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hopkinson Craig C.EVP R&D, Chief Medical OfficerAug 03 '26Option Exercise24.485,000122,40478,389Aug 03
snyderman nancy lynn MDDirectorAug 03 '26Option Exercise46.7244,4722,077,73259,867Aug 03
Gaffin David JosephEVP, CLO, Alkermes, Inc.Aug 03 '26Sale48.582,03498,812225,456Aug 03
Hopkinson Craig C.EVP R&D, Chief Medical OfficerAug 03 '26Sale48.589,000437,22069,389Aug 03
snyderman nancy lynn MDDirectorAug 03 '26Sale50.3544,4722,239,07615,395Aug 03
Gaffin David JosephEVP, CLO, Alkermes, Inc.Jul 06 '26Sale54.032,034109,897227,490Jul 06
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJul 01 '26Option Exercise19.345,00096,70082,389Jul 01
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJul 01 '26Sale51.519,000463,62173,389Jul 01
Wright Christopher IDirectorJun 12 '26Sale45.102,00090,20025,680Jun 12
Gaffin David JosephEVP, CLO, Alkermes, Inc.Jun 04 '26Sale43.052,03487,564229,524Jun 04
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 01 '26Option Exercise19.345,00096,70086,389Jun 01
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 01 '26Sale41.679,000375,04477,389Jun 01
Parisi Samuel JosephVP, Finance (Interim PAO)May 29 '26Sale42.3616,217687,0077,717May 29
Parisi Samuel JosephVP, Finance (Interim PAO)May 29 '26Option Exercise19.4816,217315,97823,934May 29
Wright Christopher IDirectorMay 21 '26Option Exercise0.006,142029,155May 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.